BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17525484)

  • 1. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas.
    Giordano TJ
    Endocr Pathol; 2006; 17(4):355-63. PubMed ID: 17525484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling in adrenocortical neoplasia.
    Assie G; Giordano TJ; Bertherat J
    Mol Cell Endocrinol; 2012 Mar; 351(1):111-7. PubMed ID: 22056416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
    Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.
    Wang C; Sun Y; Wu H; Zhao D; Chen J
    Histopathology; 2014 Mar; 64(4):567-76. PubMed ID: 24102952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular markers and the pathogenesis of adrenocortical cancer.
    Soon PS; McDonald KL; Robinson BG; Sidhu SB
    Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Diagnostic Approach to Adrenocortical Tumors.
    Hodgson A; Pakbaz S; Mete O
    Surg Pathol Clin; 2019 Dec; 12(4):967-995. PubMed ID: 31672302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nestin as a marker in the classification of adrenocortical tumors.
    Lachenmayer A; Lichtenauer UD; Cox T; Schott M; Malendowicz LK; Goretzki PE; Cupisti K; Scherbaum WA; Bornstein SR; Willenberg HS
    Horm Metab Res; 2009 May; 41(5):397-401. PubMed ID: 19294612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
    Blanes A; Diaz-Cano SJ
    Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discerning malignancy in resected adrenocortical neoplasms.
    Sasano H; Suzuki T; Moriya T
    Endocr Pathol; 2001; 12(4):397-406. PubMed ID: 11914473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms.
    Erickson LA; Jin L; Sebo TJ; Lohse C; Pankratz VS; Kendrick ML; van Heerden JA; Thompson GB; Grant CS; Lloyd RV
    Endocr Pathol; 2001; 12(4):429-35. PubMed ID: 11949624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adrenocortical tumors with neuroendocrine differentiation].
    Kazantseva IA; Poliakova GA; Gurevich LG; Morozov IA; Bezuglova TV; Smirnov VB
    Arkh Patol; 2002; 64(5):8-13. PubMed ID: 12575533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours.
    Schmitz KJ; Helwig J; Bertram S; Sheu SY; Suttorp AC; Seggewiss J; Willscher E; Walz MK; Worm K; Schmid KW
    J Clin Pathol; 2011 Jun; 64(6):529-35. PubMed ID: 21471143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?
    Bulzico D; Faria PAS; Maia CB; de Paula MP; Torres DC; Ferreira GM; Pires BRB; Hassan R; Abdelhay E; Vaisman M; Vieira Neto L
    Endocrine; 2017 Nov; 58(2):276-288. PubMed ID: 28887601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex.
    Szajerka A; Dziegiel P; Szajerka T; Zabel M; Winowski J; Grzebieniak Z
    Anticancer Res; 2008; 28(5B):2959-65. PubMed ID: 19031940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenocortical carcinoma: review and update.
    Erickson LA; Rivera M; Zhang J
    Adv Anat Pathol; 2014 May; 21(3):151-9. PubMed ID: 24713984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms.
    Enriquez ML; Lal P; Ziober A; Wang L; Tomaszewski JE; Bing Z
    Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):141-5. PubMed ID: 22553814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of aromatase and estrogen receptors in human adrenocortical tumors.
    Barzon L; Masi G; Pacenti M; Trevisan M; Fallo F; Remo A; Martignoni G; Montanaro D; Pezzi V; Palù G
    Virchows Arch; 2008 Feb; 452(2):181-91. PubMed ID: 18157729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myxoid adrenocortical neoplasms: a study of the clinicopathologic features and EGFR gene status of ten Chinese cases.
    Zhang J; Sun J; Liang Z; Gao J; Zeng X; Liu T
    Am J Clin Pathol; 2011 Nov; 136(5):783-92. PubMed ID: 22031318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.